NewsDialy
A federal judge has temporarily blocked Colorado from capping the price of Amgen's Enbrel, dealing a setback to state-level drug affordability efforts.
Separately, a new Centers for Medicare & Medicaid Services program will make obesity medicines — including Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo — available to millions of older Americans for $50 a month.
The two developments reflect the competing forces reshaping prescription drug access in the United States.
What Colorado's Drug Affordability Board Was Trying to Do An upper payment limit is a price ceiling: a cap on the maximum amount patients and payers can be charged for a specific drug.
Keep reading